Evidence map›Paper›PMID 35352940›Full record

ArticleMicrobiology spectrum2022

Fosfomycin Susceptibility Testing Using Commercial Agar Dilution Test.

Peter D Croughs, Michelle Konijnendijk-de Regt, Erlangga Yusuf

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Evaluation of theFrontiers in microbiology · 2024
    Article
  4. Intravenous Fosfomycin for Systemic Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023
    Review
  5. Fosfomycin resistance mechanisms inFrontiers in cellular and infection microbiology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Peter D CroughsDepartment of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.
Michelle Konijnendijk-de RegtDepartment of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.
Erlangga YusufDepartment of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, the Netherlands.ORCID 0000-0003-4779-2191
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The reference standard for fosfomycin antimicrobial susceptibility testing (AST) is agar dilution, but it is laborious and is not routinely used in diagnostic microbiology. In this study, we evaluated the performance of a ready-to-use commercially available agar dilution kit for fosfomycin AST (Liofilchem Diagnostics). We compared this kit with the reference standard agar dilution, performed according to the Clinical & Laboratory Standards Institute (CLSI) in 229 clinical isolates. The isolates were selected to represent both Gram-positive and Gram-negative microorganisms, with various MIC values. It consisted of 43 enterococci (E. faecalis

Indexed as

FosfomycinMethicillin-Resistant Staphylococcus aureusAgarAnti-Bacterial AgentsEnterococcusEscherichia coliMicrobial Sensitivity TestsReproducibility of ResultsAgarAnti-Bacterial AgentsFosfomycinagar dilutionantimicrobial susceptibility testingfosfomycin

Identifiers

PMID35352940
PMCPMC9045359
OpenAlexW4220769168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.